DOCSLIB.ORG

Radiation Therapy for Non-Hodgkin's Lymphoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Radiation Therapy for Non-Hodgkin's Lymphoma CLINICAL GUIDELINES Radiation Therapy Version 2.0.2019 Effective July 1, 2019 Independent licensee of the Blue Cross Blue Shield Association. Independence has delegated precertification/preapproval for outpatient, non-emergent radiation therapy services to eviCore. eviCore utilizes the Radiation Therapy Clinical Guidelines for medical necessity review of delegated radiation therapy services. © 2019 eviCore healthcare. All rights reserved. Radiation Therapy Criteria V2.0.2019 Table of Contents Hyperthermia 6 Image-Guided Radiation Therapy (IGRT) 9 Neutron Beam Therapy 13 Proton Beam Therapy 15 Radiation Therapy for Anal Canal Cancer 57 Radiation Therapy for Bladder Cancer 60 Radiation Therapy for Bone Metastases 63 Radiation Therapy for Brain Metastases 68 Radiation Therapy for Breast Cancer 76 Radiation Therapy for Cervical Cancer 87 Radiation Therapy for Endometrial Cancer 94 Radiation Therapy for Esophageal Cancer 101 Radiation Therapy for Gastric Cancer 106 Radiation Therapy for Head and Neck Cancer 109 Radiation Therapy for Hepatobiliary Cancer 113 Radiation Therapy for Hodgkin’s Lymphoma 119 Radiation Therapy for Kidney and Adrenal Cancer 123 Radiation Therapy for Multiple Myeloma and Solitary Plasmacytomas 125 Radiation Therapy for Non-Hodgkin’s Lymphoma 129 Radiation Therapy for Non-malignant Disorders 134 Radiation Therapy for Non-Small Cell Lung Cancer 152 Radiation Therapy for Oligometastases 163 Radiation Therapy for Other Cancers 173 Radiation Therapy for Pancreatic Cancer 174 Radiation Therapy for Primary Craniospinal Tumors and Neurologic Conditions 180 Radiation Therapy for Prostate Cancer 188 Radiation Therapy for Rectal Cancer 197 Radiation Therapy for Skin Cancer 200 Radiation Therapy for Small Cell Lung Cancer 208 Radiation Therapy for Soft Tissue Sarcomas 211 Radiation Therapy for Testicular Cancer 217 Radiation Therapy for Thymoma and Thymic Cancer 220 Radiation Therapy for Urethral Cancer and Upper Genitourinary Tract Tumors 224 Radiation Treatment with Azedra 226 Radiation Treatment with Lutathera 229 Radioimmunotherapy with Zevalin 234 Selective Internal Radiation Therapy 245 ______________________________________________________________________________________________________ © 2019 eviCore healthcare. All Rights Reserved. Page 1 of 250 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Radiation Therapy Criteria V2.0.2019 Please note the following: CPT Copyright 2017 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. ______________________________________________________________________________________________________ © 2019 eviCore healthcare. All Rights Reserved. Page 2 of 250 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Radiation Therapy Criteria V2.0.2019 Please note the following: All information provided by the NCCN is “Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™)©2018/2019 National Comprehensive Cancer Network. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.” ______________________________________________________________________________________________________ © 2019 eviCore healthcare. All Rights Reserved. Page 3 of 250 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Radiation Therapy Criteria V2.0.2019 Dear Provider, This document provides detailed descriptions of eviCore’s basic criteria (also known as clinical guidelines) for radiation therapy arranged by diagnosis. They have been carefully researched and are continually updated in order to be consistent with the most current evidence-based guidelines and recommendations for the provision of radiation therapy from national medical societies and evidence-based medicine research centers. In addition, the criteria are supplemented by information published in peer-reviewed literature. Our health plan clients review the development and application of these criteria. Every eviCore health plan client develops a unique list of CPT codes or diagnoses that are part of their radiation therapy utilization management programs. Health Plan medical policy supersedes the eviCore criteria when there is conflict with the eviCore criteria and the health plan medical policy. If you are unsure of whether or not a specific health plan has made modifications to these basic criteria in their medical policy for Radiation Therapy please contact the plan or access the plan’s website for additional information. While eviCore encourages participation in clinical trials when consistent with each health plan’s policies, we want to clarify our position on the use of such standard arms outside of the research setting. The use of a control arm or standard arm in a Phase III clinical trial does not necessarily mean that other standard treatment techniques are not equally effective. Examples of multiple “standard” arms can easily be found in the treatment of prostate cancer where Intensity-Modulated Radiation Therapy (IMRT), 3-Dimensional (3-D), low dose implant or High Dose Rate (HDR) can be equally effective or breast cancer where standard whole breast fractionation or hypo-fractionation can be used. Indeed, national criteria such as National Comprehensive Cancer Network ______________________________________________________________________________________________________ © 2019 eviCore healthcare. All Rights Reserved. Page 4 of 250 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Radiation Therapy Criteria V2.0.2019 (NCCN) and American College of Radiology (ACR) Appropriateness Criteria often suggest more than one radiation technique. It is eviCore’s process to apply evidence-based criteria to the particular clinical characteristics in evaluating a case, and to certify the most appropriate regimen/modality. This regimen/modality may match one that is used as a “standard arm” in a federally funded clinical trial, or it may be one that is considered an “alternate standard”. The alternate standard will be one supported by nationally published guidelines such as the NCCN, ACR Appropriateness Guidelines, or American Society for Radiation Oncology (ASTRO) Evidence- Based Guidelines, or supported by other acceptable peer-reviewed publications. As such, eviCore will not automatically certify a case based solely on the fact that it matches the standard (control) arm of a clinical trial. This concept applies also to regimens/modalities listed by the NCCN or ACR as “acceptable” treatments for specific disease sites. Rather, we commit to working with the providing Radiation Oncologist to certify the most appropriate regimen/modality for a particular case. eviCore healthcare works hard to make your clinical review experience a pleasant one. For that reason, we have peer reviewers available to assist you should you have specific questions about a procedure. For your convenience, eviCore’s Customer Service support is available from 7 a.m. to 7 p.m. Our toll free number is (800) 918-8924. Gregg P. Allen, M.D. FAAFP EVP and Chief Medical Officer ______________________________________________________________________________________________________ © 2019 eviCore healthcare. All Rights Reserved. Page 5 of 250 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Radiation Therapy Criteria V2.0.2019 Hyperthermia POLICY I. The use of hyperthermia and concurrent radiation therapy treatment is medically necessary for any of the following: A. Superficially recurrent melanoma B. Chest wall recurrence of breast cancer C. Recurrent cervical lymph nodes from head and neck cancer Treatment of the above conditions will be approved in the absence of both of the following: D. Metastatic disease for which chemotherapy or hormonal therapy is being given concurrently or planned E. Evidence of tumor recurrence exceeding 4 cm in depth When hyperthermia is indicated, no more than 10 hyperthermia treatments delivered twice weekly at 72-hour intervals should be utilized. II. The use of intraluminal, endocavitary, interstitial, regional deep tissue hyperthermia exceeding 4 cm in depth, and whole body hyperthermia is considered experimental, investigational, or unproven (EIU) Key Clinical Points After initial enthusiasm for the use of hyperthermia in the late 1970s, interest waned with the publication of studies showing little or no benefit in the mid-1980s. Later review of the negative findings disclosed that the critical temperature necessary for hyperthermic cell death, 42 to 43 degrees centigrade (C), was either poorly measured or poorly maintained in these studies. Point measurements rather than volume mapping of thermal gradients were relied upon in planning these hyperthermia studies. Renewed interest in the use of hyperthermia began to emerge in both Europe and the United States (US) in the 1990s. Research from Duke University, Northwestern University, University of Southern California, Stanford University, Washington University, as well as centers in Holland, Germany, Norway, Austria, Italy, and Switzerland have contributed substantially to the emergence of hyperthermia as a useful treatment modality when combined with radiation therapy. Currently, in the US, the Food and Drug Administration (FDA) has approved hyperthermia for
Load more

Recommended publications
  • ICD-9 Diagnosis Codes Effective 10/1/2011 (V29.0) Source: Centers for Medicare and Medicaid Services
    ICD-9 Diagnosis Codes effective 10/1/2011 (v29.0) Source: Centers for Medicare and Medicaid Services 0010 Cholera d/t vib cholerae 00801 Int inf e coli entrpath 01086 Prim prg TB NEC-oth test 0011 Cholera d/t vib el tor 00802 Int inf e coli entrtoxgn 01090 Primary TB NOS-unspec 0019 Cholera NOS 00803 Int inf e coli entrnvsv 01091 Primary TB NOS-no exam 0020 Typhoid fever 00804 Int inf e coli entrhmrg 01092 Primary TB NOS-exam unkn 0021 Paratyphoid fever a 00809 Int inf e coli spcf NEC 01093 Primary TB NOS-micro dx 0022 Paratyphoid fever b 0081 Arizona enteritis 01094 Primary TB NOS-cult dx 0023 Paratyphoid fever c 0082 Aerobacter enteritis 01095 Primary TB NOS-histo dx 0029 Paratyphoid fever NOS 0083 Proteus enteritis 01096 Primary TB NOS-oth test 0030 Salmonella enteritis 00841 Staphylococc enteritis 01100 TB lung infiltr-unspec 0031 Salmonella septicemia 00842 Pseudomonas enteritis 01101 TB lung infiltr-no exam 00320 Local salmonella inf NOS 00843 Int infec campylobacter 01102 TB lung infiltr-exm unkn 00321 Salmonella meningitis 00844 Int inf yrsnia entrcltca 01103 TB lung infiltr-micro dx 00322 Salmonella pneumonia 00845 Int inf clstrdium dfcile 01104 TB lung infiltr-cult dx 00323 Salmonella arthritis 00846 Intes infec oth anerobes 01105 TB lung infiltr-histo dx 00324 Salmonella osteomyelitis 00847 Int inf oth grm neg bctr 01106 TB lung infiltr-oth test 00329 Local salmonella inf NEC 00849 Bacterial enteritis NEC 01110 TB lung nodular-unspec 0038 Salmonella infection NEC 0085 Bacterial enteritis NOS 01111 TB lung nodular-no exam 0039
    [Show full text]
  • Chronic Sinusitis
    CHRONIC SINUSITIS BY DR AYUB AHMAD KHAN MBBS,MCPS(ENT),FCPS(ENT),MCPS(HPE), BACO FELLOWSHIP(UK),HOUSE EAR INSTITUTE FELLOWSHIP(USA) Professor/consultant ENT Head of E.N.T. Department Medical educationist CPSP & UHS certified faculty master trainer University college of medicine University of Lahore 1 Ground Rules • Be on time • Put your mobile phones on silent • Participate actively • Have a little fun on the way 2 3 4 5 6 7 8 9 10 Learning outcomes By the end of the session the participants will be able to Describe Chronic Sinusitis and its types Describe clinical presentations of Chronic sinusitis Describe the investigations required to be done for Chronic sinusitis Describe the treatment options for different types of Chronic sinusitis 12 Rhinosinusitis May be Better Term Because Allergic or nonallergic rhinitis nearly always precedes sinusitis Sinusitis without rhinitis is rare Nasal discharge and congestion are prominent symptoms of sinusitis Nasal mucosa and sinus mucosa are similar and are contiguous Differentiating Sinusitis from Rhinitis Rhinitis Sinusitis Nasal congestion Nasal congestion Rhinorrhea clear Purulent rhinorrhea Itching, red eyes Postnasal drip Seasonal symptoms Headache Nasal crease Facial pain Cough, fever Anosmia 15 16 Normal Sinus Sinus health depends on: Mucous secretion of normal viscosity, volume, and composition. Normal muco-ciliary flow to prevent mucous stasis and subsequent infection. Open sinus ostia to allow adequate drainage and aeration. Definition Inflammation of the mucosal lining of the paranasal sinuses. Acute, subacute, and chronic. One of the most common diseases. Definition Acute-up to 3 weeks Subacute-3 weeks to 3 months Chronic-more than 3 months Epidemiology Affects 30-35 million persons/year.
    [Show full text]
  • New Emergency Room Requirement for Hospital and Autopay List of Diagnosis Codes
    Provider update New emergency room requirement for hospitals Dell Children’s Health Plan reviewed our emergency room (ER) claims data and identified numerous reimbursements for services with diagnoses that are not indicative of urgent or emergent conditions. As a managed care organization, we promote the provision of services in the most appropriate setting and reinforce the need for members to coordinate care with their PCP unless the injury or sudden onset of illness requires immediate medical attention. Effective on or after August 1, 2020, for nonparticipating hospitals and on or after October 1, 2020, for participating hospitals, Dell Children’s Health Plan will only process an ER claim for a hospital as emergent and reimburse at the applicable contracted rate or valid out‐ of‐network Medicaid fee‐for‐service rate when a diagnosis from a designated auto‐pay list is billed as the primary diagnosis on the claim. If the primary diagnosis is not on the auto‐pay list, the provider must submit medical records with the claim. Upon receipt, the claim and records will be reviewed by a prudent layperson standard to determine if the presenting symptoms qualify the patient’s condition as emergent. If the reviewer confirms the visit was emergent, according to the prudent layperson criteria, the claim will pay at the applicable contracted rate or valid out‐of‐network Medicaid fee‐for‐service rate. If it is determined to be nonemergent, the claim will pay a triage fee. In the event a claim from a hospital is submitted without a diagnosis from the auto‐pay list as the primary diagnosis and no medical records are attached, the claim for the ER visit will automatically pay a triage fee.
    [Show full text]
  • Pathological Basis of Respiratory System Diseases
    Pathological basis of respiratory system diseases Jasim M A Al-Diab Professor of Pathology Basrah Medical college Learning Objectives (2018/2019) Nose, Nasal sinuses & Nasopharynx -Pathology of inflammatory diseases; rhinitis, sinusitis, and nasopharyngitis -Granulomatous lesions -Benign and malignant tumors and tumor like lesions -Tumors of the larynx Obstructive pulmonary diseases (airway diseases) -Pathological bases of decreased expiratory flow rate -Pathology of bronchial asthma -Pathology of bronchiectasis -Pathology of chronic bronchitis -Pathology of pulmonary emphysema Restrictive pulmonary diseases -Diffuse interstitial lung diseases -Pathology of acute respiratory destress syndrome (ARDS) -Pathology of chronic restrictive pulmonary diseases -Pneumoconiosis -Interstitial fibrosis of unknown etiology -Infiltrative conditions -The outcome of chronic restrictive pulmonary diseases -Honey comb lung Lung Atelectasis -Definition -Types -Pathology and effects Pneumonia Jasim M Al-Diab Professor of Pathology Basrah Medical College 2018-2019 -Definition -Classification -Pathology of bronchopeumonia -Pathology of lobar pneumonia Pulomonary hypertension -Definitiom -Pathogenesis and causes -Pathological changes in pulmonary microcirculation Tumors of the lungs and bronchi -WHO classification of lung carcinoma -The four major histological types - Pancoast’s tumor -Pancoast’s syndrom Tumors of the pleura -Benign mesothelioma -Malignant mesothelioma Nose, Nasal sinuses & Nasopharynx Acute Rhinitis Infectious rhinitis (common cold); viral
    [Show full text]
  • Lymphoid Lesions of the Head and Neck: a Model of Lymphocyte Homing and Lymphomagenesis Elaine S
    Lymphoid Lesions of the Head and Neck: A Model of Lymphocyte Homing and Lymphomagenesis Elaine S. Jaffe, M.D. Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland Lymphomagenesis is not a random event but is Lymphoid lesions of the head and neck mainly affect usually site specific. It is dependent on lymphocyte the nasopharynx, nasal and paranasal sinuses, and homing, as well as the underlying biology and func- salivary glands. These three compartments each are tion of the resident lymphoid tissues. The head and affected by a different spectrum of lymphoid malig- neck region contains several compartments: the na- nancies and can serve as model for mechanisms of sopharynx, nasal and paranasal sinuses, and sali- lymphomagenesis. The type of lymphoma seen re- vary glands, each of which is affected by a different flects the underlying biology and function of the par- subset of benign and neoplastic lymphoid prolifer- ticular site involved. The nasopharynx and Waldeyer’s ations (Table 1). These three sites can serve as a ring are functionally similar to the mucosal associated model of lymphomagenesis that can be extended to lymphoid tissue (MALT) of the gastrointestinal tract other organ systems. Indeed, the head and neck and are most commonly affected by B-cell lympho- region can serve as a microcosm for understanding mas, with mantle cell lymphoma being a relatively the principles of lymphoma classification and the frequent subtype. The most prevalent lymphoid lesion distribution of lymphoma subtypes in other organ of the salivary gland is lymphoepithelial sialadenitis, systems. associated with Sjögren’s syndrome. Lymphoepithe- The nasopharynx normally contains abundant lial sialadenitis is a condition in which MALT is ac- lymphoid tissue.
    [Show full text]
  • IAO International Archives of Otorhinolaryngology
    International Archives of IAO Otorhinolaryngology ProfOrganizing. Ricardo Committee F erreira Bento Virtual Congress of theHe Otorhinolaryngologyaring & Balanc Foundatione 2017 PreProf.sident Dr. Richard Louis Voegels DrProf.. RDr.obinson Ricardo Ferreira Koji Bento Tsu ji President of Scientific Comission Dra. Ana Carolina Fonseca General Secretary 2020 OFFICIAL PROGRAM ABSTRACTS CCALLALL FFOROR PPAPERSAPERS YYouou areare invitedinvited to to submit submi tthe th efull ful articlesl article presenteds presente atd at VirVirtualth Congress Congress of Otorhinolaryngology of Otorhinolaryngology Foundation Foundation free free of of cost to thethe InternationalInternational ArchiArchivesves ofof OtorhinolaryngologyOtorhinolaryngology.. IAO is an international peer-reviewed journal focusing on disorders of the ear, nose, mouth, pharynx, larynx, cervical region, upper airway system, audiology and communication disorders. Published quarterly, the journal covers the entire spectrum of otorhinolaryngology – from prevention, to diagnosis, treatment and rehabilitation. ISSN 1809–9777 International Archives of IAO Otorhinolaryngology Editor in Chief Issue 3 • Volume 24 • July – August – September 2020 Why publish in IAO? Geraldo Pereira Jotz Co-Editor Aline Gomes Bittencourt • Rigorous Peer-Review by Leading Specialists. • International Editorial Board. • Continuous Publication: Speeding up the Publication of Articles. • Web-based Manuscript Submission. • Complete Free Online Access to all Published Articles via Thieme E-Journals at www.thieme-connect.com/products
    [Show full text]
  • Granulomatous Diseases of the Head and Neck
    GRANULOMATOUS DISEASES OF THE HEAD AND NECK S H A R O N R A M O S , M D FAFRRAH SIDDIQUI , M D THE UNIVERSITY OF TEXAS MEDICAL BRANCH DEPARTMENT OF OTOLARYNGOLOGY GRAND ROUNDS PRESENTATION FEBRUARY 27, 2013 OUTLINE • Granuloma? • Bacterial • Fungal • Autoimmune/vasculitis • Neoplastic GRANULOMA • Pathophysiology • Is a type of chronic inflammation • Neutrophils usually remove agents that initiate an acute inflammatory response by phagocytosis and digestion. If an agent is indigestible it provokes a vicious cycle of acute inflammatory response s that can cause local tissue damage. The body deals with these reactions by forming granulomas. GRANULOMAS • The principle cells involved in granulomatous inflammation macrophages and lymphocytes • Macrophages live longer than neutrophils and can phagocytose an indigestible agent. This causes macrophage to lose their motility and thus accumulate at the site of injury. • Macrophages undergo structural changed and become epithelioid cells (larger with more cytoplasm, resemble epithelial cells). These cells (50+) can fuse together and form multinucleated giant cells. • Lymphocytes surround these cells. • When the nuclei of these giant cells form a horse show pattern, the cell is named a “Langhans Giant Cells”. GRANULOMA Caseous refers to a form of necrosis that can be seen without a microscope, “cheese-like” appearance BACTERIAL INFECTIONS CAT SCRATCH DISEASE • Bartonella Henselae • Gram negative rod • Hx of cat exposure in 90% of patients • Mainly affects children and adolescents • Clinical Manifestations
    [Show full text]
  • Lethal Midline Granuloma: a Case Report
    Case report 131 Lethal midline granuloma: a case report Salman Ahmed Mangrioa, Rahim Dhanania, Mubasher Ikrama, Muhammad Usman Tariqb aSection of ENT/Head and Neck Surgery, The rarity of lethal midline granuloma and lack of knowledge by the majority of b Department of Surgery, Section of clinicians about this disease makes this disease a difficult entity to diagnose. Histopathology, Department of Pathology and Laboratory Medicine, Aga Khan University Nonspecific symptoms of this disease present obstacles in correct diagnosis and Hospital, Karachi, Pakistan lead to a delay in proper treatment. Surgeons play a limited role in this condition. We present a case report of a 38-year-old man with this rare condition. Correspondence to Dhanani Rahim, MBBS, Block 3-E/II, Flat number 604 Alkausar homes, Nazimabad near gole market, Karachi, 74800, Keywords: Pakistan; Tel: +92 300 394 5260; lethal midline granuloma, lymphoma, T-cell lymphoproliferative disorder fax: 92 21 3493 4294; Egypt J Otolaryngol 33:131–133 e-mail: [email protected] © 2017 The Egyptian Journal of Otolaryngology Received 17 September 2016 1012-5574 Accepted 6 October 2016 The Egyptian Journal of Otolaryngology 2017, 33:131–133 lymphadenopathy. A pedicel flap was also seen Introduction around the right-side of the face, which represented a Lethal midline granuloma syndrome (LMG) is a very previous unsuccessful attempt at reconstructive surgery rare condition with a difficult diagnosis because of the (Fig. 1). nonspecificity of the symptoms with which it presents and the widespread array of diseases related to it. It was The patient was admitted to the ward and subjected to first described in 1897, and later it was given multiple laboratory investigations, which revealed low hemoglobin names.
    [Show full text]
  • IX./1.: Non Tumour Lesions of the Larynx
    IX./1.: Non tumour lesions of the larynx IX./1.1.: Developmental anomalies Symptoms: breathing problems, distorted sound of crying, swallowing problems Diagnosis: direct laryngoscopy, bronchoscopy, oesophagoscopy, imaging tests (CT, MR). The cooperation of otorhinolaryngologists, pediatricians, surgeons, anesthesiologists is needed. The diagnosis is not easy; the result is not always satisfactory. Forcing diagnosis or treatment may lead to the worsening of the patient’s condition. Congenital anomalies of the larynx: Cartilage anomalies: laryngomalacia (congenital stridor); epiglottis anomalies (missing epiglottis, epiglottis bifida); thyroid cartilage anomalies (the wings do not grow together at the middle line, horns are missing ); arytenoid-cartilage anomalies; cricoid-cartilage anomalies (subglottic stenosis, the posterior lamella remains open); soft tissue anomalies: sulcus glottidis, sulcus chordae vocalis; cysts and laryngoceles (internal, external, and combined laryngocele); scars, stenoses, and atresies; cry du chat (cat cry) syndrome; nerve lesions (unilateral or bilateral nerve paralysis ; vascular anomalies: hemangiomas, lymphangiomas. Laryngomalacia It is the most frequent congenital anomaly. In fact it is not the ’malacia’ of the laryngeal cartilages, but due to the softness of the immature laryngeal cartilages the negative pressure of inhaling pulls the epiglottis, the aryepiglottic folds and the ary regions over the lumen of the larynx causing respiratory stridor. This is definitely inspiratory stridor, which can be constant or changing depending on the position of the neonate, but the crying sound remains normal. As the neonate is maturing the stridor will gradually abate and finally stop and so treatment is not necessary. Laryngeal diaphragm Diaphragm is generally the longer or shorter scarred coalescence of the frontal part of the vocal folds.
    [Show full text]
  • Computed Tomography of Lethal Midline Granuloma
    대 한방사선 의 학회 지 1991; 27(4) : 513~517 Journal of Korean Radiological Society, July, 1991 Computed Tomography of Lethal Midline Granuloma Ho Suk Lee, M.D., Tae Ho Kim, M.D., Kyung Jin Sub, M.D., Tae Hun Kim, M.D. Yong Joo Kirn, M.D., Dul‘ Sik Kang, M.D. Department of Diagnostic Radiology, CoJ1ege of Medicine, Kyungpook National University - Ab8tract- In order to clarify the CT findings oflethal midline granuloma (LMG) diagnosed clinically or histopathologically, the authors retrospectively analyzed 12 patients who were seen at Kyungpook National University Hospital from February 1985 to August 1989. CT showed nasal mucosal thickening and/or soft tissue mass (9 cases), spreading of the lesions along the facial subcutaneous fat plane (8 cases), invasion into the paranasal sinuses (5 cases), bone destruction (5 cases), nasopharyngeal mass lesion (2 cases), and extension of the lesion into the infratemporal fossa (1 case). In spite of the fact that CT does not make definitive diagnosis of LMG, it permits evaluation of the extent of the lesion, detection of the combined lesion, differential diagnosis, and close monitoring of its evolution under treatment. Index Word8: Nose , Lethal Midline Granuloma 261.622 Paranasal sinuses. Computed Tomography 23.1211 Nose. Computed Tomography 261. 1211 Recent research on the condition historically Introduction known as lethal midline granuloma concludes that it is a form of T-cell lymphoma.(2) Since the first report ofMcBride (1897)(1). the tenn The prominent histological features ofLMG are in­ lethal midline granuloma (LMG) and it8 various f1ammation, necrosis, and thrombosis with infiltra­ synonyms-progressive lethal granulomatous 비cera­ tion of the atypical histiocytes into the perivascular tion (Stewart.
    [Show full text]
  • Lethal Midline Granuloma Importance of Early Diagnosis: a Case Report
    LETHAL MIDLINE GRANULOMA IMPORTANCE OF EARLY DIAGNOSIS: A CASE REPORT Asem El-Omari, MD* ABSTRACT Non-Hodgkin’s lymphomas of the sinonasal region are uncommon. They are included in the so-called non-healing midline granuloma syndrome, which is characterized by slowly progressive deep midfacial destruction of soft tissue, cartilage, and bone. Many terms have been used in the literature such as malignant reticulosis or polymorphic reticulosis. A case of high-grade lymphoma is reported, and it is diagnosed in a very late stage as it was mistaken for inflammatory disease and treated medically for several months as a dacryocystitis. When appropriately diagnosed a combined radio- and chemotherapy was offered to the patient, but follow up of patient revealed that he was died at home after 3 weeks of treatment. Key words: Lethal midline granuloma, Non-Hodgkin’s lymphoma, Epstein Barr virus, T-cell lymphoma. JRMS June 2004; 11(1): 44-45 inflammatory cells intermingled with large typical Introduction (4) Angiocentric sinonasal T-cell lymphoma is a non- lymphoid cells . Additionally, diagnostic confusion Hodgkin lymphoma; rare in Western countries but may result from the variety of pathologic terms that have common in Asia and China. It has an association with been applied to this lesion over years including (1) polymorphic reticulosis, lethal midline granuloma, and Epstein-Barr virus . It is a confusing terminology (5) previously described to include Wegener’s midline malignant reticulosis . Angiocentric Granulomatosis, Polymorphic reticulosis, idiopathic lymphomas also have been reported in other extranodal sites, such as the skin, soft tissue, testis, upper respiratory midline destructive diseases, and non-Hodgkin (6) lymphomas now separated into Wegener’s tract, and gastrointestinal tract .
    [Show full text]
  • Midline Lethal Granuloma Complicating Pregnancy: Case Report B.D.O
    July 2003 EAST AFRICAN MEDICAL JOURNAL 391 East African Medical Journal Vol. 80. No. 7 July 2003 MIDLINE LETHAL GRANULOMA COMPLICATING PREGNANCY: CASE REPORT B.D.O. Saheeb, BDS, FWACS, FICS, FDS, RCS (Edin) Senior Lecturer/Consultant, and M.A. Ojo, BDS, MMed Sc, Dip Maxfac Rad, Associate Professor/Consultant Department of oral and Maxillofacial Surgery and Pathology, University of Benin Teaching Hospltal, Benin City, Nigeria. Request for reprints to: Dr. B.D.O. Saheeb, P.O Box 2799, Benin City, Edo State, 300-001, Nigeria MIDLINE LETHAL GRANULOMA COMPLICATING PREGNANCY: CASE REPORT B.D.O. SAHEEB and M.A. OJO ABSTRACT A case of midline lethal granuloma in a 28-year- old female Nigerian patient is reported. Oral, ocular and nasal lesions were present and these preceded a spontaneous abortion of a three month old pregnancy. The clinical course of the disease and its similarity to other granulomatous diseases, which are generally classified as midline granuloma syndrome, are highlighted. The prognosis is poor but early diagnosis and treatment appears to improve a patient’s condition INTRODUCTION CASE REPORT The term “midline granuloma syndrome” (MGS) is A 28-year-old Nigerian woman presented in our Oral and Maxillofacial Surgery clinic with a history of oro-nasal clinically used to describe a abroad spectrum of diseases fenestration and swelling of the left eye of a 4-month duration. characterised by aggressive and progressive destruction She had complained of a gradual deterioration of vision in the left of the mucosa and adjacent structures of the midline and eye and a purulent discharge from the nose.
    [Show full text]